Private Advisor Group LLC Sells 13,174 Shares of Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Private Advisor Group LLC reduced its stake in Moderna by 54.9%, selling 13,174 shares in the first quarter, leaving it with 10,806 shares valued at approximately $306,000.
• Moderna's stock has traded down 8.1% recently, with current prices around $29.56, significantly lower than its 12-month high of $122.45.
• Analyst ratings are mixed, with 17 holding a "hold" rating and a consensus target price of $46.11, indicating cautious optimism amidst overall declines in stock performance.

Private Advisor Group LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 54.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,806 shares of the company's stock after selling 13,174 shares during the period. Private Advisor Group LLC's holdings in Moderna were worth $306,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Sentry Investment Management LLC purchased a new stake in shares of Moderna in the first quarter valued at about $31,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after purchasing an additional 392 shares during the last quarter. Itau Unibanco Holding S.A. raised its holdings in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after purchasing an additional 343 shares during the last quarter. Vega Investment Solutions purchased a new stake in shares of Moderna in the fourth quarter valued at about $45,000. Finally, Versant Capital Management Inc raised its holdings in shares of Moderna by 408.9% in the first quarter. Versant Capital Management Inc now owns 1,593 shares of the company's stock valued at $45,000 after purchasing an additional 1,280 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 8.1%

MRNA stock opened at $29.56 on Friday. The firm has a 50 day moving average of $29.20 and a 200-day moving average of $30.34. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $122.45. The firm has a market capitalization of $11.43 billion, a P/E ratio of -3.39 and a beta of 1.84.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the business earned ($3.07) earnings per share. Moderna's revenue was down 35.3% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on MRNA shares. Cowen started coverage on shares of Moderna in a report on Sunday, July 13th. They issued a "hold" rating for the company. Evercore ISI lowered their target price on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Bank of America decreased their price objective on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Finally, William Blair restated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Four equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Moderna has an average rating of "Hold" and a consensus target price of $46.11.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.